AstraZeneca Posts 8.6% Q4 Revenue Growth to $58.7B, $10.2B Profit
AstraZeneca ended Q4 2025 with 8.6% revenue growth to $58.7 billion, fueled by a 48% surge in Imfinzi and Enhertu sales, driving net profit to $10.2 billion. The board raised the interim dividend by $0.07 and plans 20 Phase 3 readouts in 2026, forecasting higher revenue and core EPS.
1. AstraZeneca Q4 Earnings
AstraZeneca ended its fiscal Q4 2025 with total revenue of $58.7 billion, up 8.6% year-over-year, driven by a 48% increase in Imfinzi and Enhertu oncology sales, which formed 44% of product revenue. Net profit rose to $10.2 billion from $7.0 billion in the prior-year quarter and the board approved a $0.07 interim dividend increase.
2. Edwards Lifesciences Q4 Results
Edwards Lifesciences delivered 13.3% year-over-year Q4 sales growth, powered by strong transcatheter aortic valve replacement (TAVR) momentum and the latest SAPIEN valve, though adjusted EPS missed estimates and gross margin dipped 0.8%. The company reaffirmed its 2026 outlook of 8-10% sales growth and EPS of $2.90 to $3.05.
3. Zimmer Biomet Q4 Update
Zimmer Biomet reported Q4 revenue of $2.2 billion, up nearly 11% year-over-year, and adjusted EPS of $2.42, beating consensus by $0.04, as high orthopedic demand continued. Management reiterated EPS guidance of $8.30 to $8.45 and free cash flow growth of 8-10% for 2026, while flagging tariff headwinds.